Table 2 Patients with FEV1 decline or SGRQ deterioration in the total population
From: Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Patients with confirmed FEV1decline or SGRQ deterioration at time points after the initial decline (available assessments) | ||||||||
|---|---|---|---|---|---|---|---|---|
Months after confirmed FEV1decline or SGRQ increase | ||||||||
6 | 12 | 18 | 24 | 30 | 36 | 42 | 48 | |
FEV1decline | ||||||||
No. of patients with decline, n (%) | 1924/1924 (100) | 1239/1661 (74.6) | 1091/1447 (75.4) | 895/1199 (74.6) | 754/966 (78.1) | 604/755 (80.0) | 419/549 (76.3) | 280/343 (81.6) |
Mean FEV1 change from baseline, mL (SD) | −223 (114) | −193 (176) | −202 (187) | −214 (195) | −237 (212) | −256 (224) | −258 (230) | −280 (224) |
Median FEV1 change from baseline mL (min, max) | −190 (−1090, −40) | −180 (−1240, 850) | −200 (−1000, 0.630) | −210 (−1070, 0.740) | −240 (−1190, 650) | −240 (−1200, 490) | −250 (−980, 460) | −270 (−920, 670) |
SGRQ deterioration | ||||||||
No. of patients with deterioration, n (%) | 1785/1785 (100) | 1140/1510 (75.5) | 941/1301 (72.3) | 776/1067 (72.7) | 629/843 (74.6) | 462/617 (74.9) | 303/388 (78.1) | |
Mean SGRQ change from baseline (SD) | 12.5 (7.5) | 10.6 (10.7) | 10.2 (11.4) | 10.7 (12.3) | 11.3 (12.6) | 11.8 (12.8) | 12.3 (12.8) | |
Median SGRQ score change from baseline (min, max) | 10.5 (4.0, 53.1) | 9.5 (−48.4, 53.9) | 9.3 (−44.2, 67.8) | 10.2 (−44.5, 69.6) | 10.7 (−36.6, 54.6) | 10.9 (−33.8, 50.1) | 11.9 (−29.8, 47.3) | |